430 results on '"Intranasal immunization"'
Search Results
2. An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge.
- Author
-
Deng, Huixiong, Li, Yanlei, He, Xuanting, Wang, Haoyang, Wang, Shenmiao, Zhang, Hengyao, Zhu, Jiacheng, Gu, Liming, Li, Rui, and Wang, Gefei
- Subjects
CELLULAR evolution ,GENETIC mutation ,RNA sequencing ,VACCINE effectiveness ,IMMUNIZATION ,HUMORAL immunity - Abstract
Coxsackievirus B3 (CVB3) triggers viral myocarditis, with no effective vaccine yet. This fecal‐oral transmitted pathogen has prompted interest in mucosal immunization strategies to impede CVB3 spread. We developed a new attenuated vaccine strain, named CVB3(mu). The potential of CVB3(mu) to stimulate mucosal immune protection remains to be elucidated. This study evaluates the attenuation characteristics of CVB3(mu) via a rapid evolution cellular model and RNA sequencing. Its temperature sensitivity and safety were evaluated through in vitro and in vivo experiments. The mucosal immunity protection of CVB3(mu) was assessed via intranasal immunization in Balb/c mice. The results indicate that CVB3(mu) exhibits temperature sensitivity and forms smaller plaques. It sustains fewer genetic mutations and still possesses certain attenuated traits up to the 25th passage, in comparison to CVB3(WT). Intranasal immunization elicited a significant serum neutralizing antibodies, and a substantial sIgA response in nasal washes. In vivo trials revealed CVB3(mu) protection in adult mice and passive protection in suckling mice against lethal CVB3(WT) challenges. In conclusion, CVB3(mu), a live attenuated intranasal vaccine, provides protection involving humoral and mucosal immunity, making it a promising candidate to control CVB3 spread and infection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Intranasal delivery of a recombinant adenovirus vaccine encoding the PEDV COE elicits potent mucosal and systemic antibody responses in mice
- Author
-
Shijie Yan, Yi Luo, Ningjia Zhan, Haoran Xu, Yao Yao, Xiang Liu, Xiaoqing Dong, Li Kang, Guozhong Zhang, and Pinghuang Liu
- Subjects
PEDV ,vaccine ,Ad5 vector ,intranasal immunization ,mucosal immune responses ,Microbiology ,QR1-502 - Abstract
ABSTRACT Porcine epidemic diarrhea virus (PEDV) is an enteropathogenic coronavirus that causes substantial economic loss to the global pig industry. The emergence of PEDV variants has increased the need for new vaccines, as commercial vaccines confer inferior protection against currently circulating strains. It is well established that the induction of mucosal immunity is crucial for PEDV vaccines to provide better protection against PEDV infection. In this study, we constructed a recombinant adenovirus expressing the core neutralization epitope (COE) of G2b PEDV based on human adenovirus serotype 5 (Ad5). We evaluated the effects of different administration routes and doses of vaccine immunogenicity in Balb/c mice. Both intramuscular (IM) and intranasal (IN) administration elicited significant humoral responses, including COE-specific IgG in serum and mucosal secretions, along with serum-neutralizing antibodies. Moreover, IN delivery was more potent than IM in stimulating IgA in serum and mucosal samples and in dampening the immune response to the Ad5 vector. The immune response was stronger after high versus low dose IM injection, whereas no significant difference was observed between high and low IN doses. In summary, our findings provide important insights for developing novel PEDV vaccines.IMPORTANCEPorcine epidemic diarrhea (PED) is a highly contagious disease that has severe economic implications for the pork industry. Developing an effective vaccine against PEDV remains a necessity. Here, we generated a recombinant adenovirus vaccine based on Ad5 to express the COE protein of PEDV (rAd5-PEDV-COE) and systematically evaluated the immunogenicity of the adenovirus-vectored vaccine using different administration routes (intramuscular and intranasal) and doses in a mouse model. Our results show that rAd5-PEDV-COE induced potent systemic humoral response regardless of the dose or immunization route. Notably, intranasal delivery was superior to induce peripheral and mucosal IgA antibodies compared with intramuscular injection. Our data provide valuable insights into designing novel PEDV vaccines.
- Published
- 2024
- Full Text
- View/download PDF
4. Protective effect of TLR2/TLR9 agonists on pulmonary Acinetobacter baumannii infection in mice
- Author
-
CHENG Hao, YANG Yun, and SUN Hongwu
- Subjects
acinetobacter baumannii ,tlr2 ,tlr9 ,intranasal immunization ,pulmonary infection ,Medicine (General) ,R5-920 - Abstract
Objective To investigate the protective effect of Toll-like receptor (TLR) 2 /TLR9 agonists, Pam2CSK4 (Pam) and CpG ODN (CpG) on mice infected with Acinetobacter baumannii (Ab) in the lungs. Methods Female C57 mice (6~8 weeks old) were randomly divided into PBS, Pam, CpG and Pam+CpG groups. In 24 h after intranasal immunization with different doses of the corresponding agonists, the mice were given a lethal dose of Ab infection in the lungs, and the survival rates of the mice were observed. A sublethal dose lung infection model of Ab was then established, and the bacterial colonization in the blood, lungs, liver, kidneys and spleen was measured respectively in the mice after infection. HE staining was used to observe the pathological damages in the lungs and kidneys. The protective effect of the agonists in the immunized mice against Ab was examined at 1, 3 and 7 d after immunization to explore the protective time window. Pam+CpG was used to stimulate A549 cells and RAW264.7 cells to investigate the killing or phagocytic effects on Ab. Results Compared to PBS, Pam+CpG treatment significantly improved the survival rate of the mice after a lethal dose of Ab lung infection (P
- Published
- 2024
- Full Text
- View/download PDF
5. Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern
- Author
-
Evgeny B. Faizuloev, Anastasiia V. Gracheva, Ekaterina R. Korchevaya, Yulia I. Ammour, Daria I. Smirnova, Darya M. Khokhlova, Andrey O. Drokov, Andrey A. Pankratov, Galina V. Trunova, Varvara A. Khokhlova, Maria S. Vorontsova, Irina A. Leneva, Oksana A. Svitich, and Vitaly V. Zverev
- Subjects
live attenuated covid-19 vaccine ,cold-adapted sars-cov-2 ,immunization efficacy ,intranasal immunization ,heterologous challenge ,cross-protective immune response ,golden syrian hamsters ,Microbiology ,QR1-502 - Abstract
Introduction. Despite the end of the COVID-19 pandemic, the problem of vaccine prevention of this disease appears highly relevant. The emergence and widespread distribution of the Omicron SARS-CoV-2 variant of concern (VOC) and its sublineages has dramatically reduced the efficacy of vaccination. The possible approach to solving this problem is to develop a nasal live attenuated vaccine capable of activating humoral, mucosal, and cell-mediated immunity, providing a prolonged immune response and cross-protection against different VOCs. The aim of the study was to determine the immunization efficacy with attenuated cold-adapted Wuhan-like SARS-CoV-2 D-D2 strain against homologous and heterologous challenges. Materials and methods. The study was conducted on an animal model of coronavirus pneumonia in golden Syrian hamsters. The efficacy of immunization was assessed by comparing the dynamics of weight, viral load in organs and histopathological changes in the lungs in immunized and unimmunized animals. Results. Single intranasal immunization of golden Syrian hamsters with D-D2 strain showed its high immunogenicity: seroconversion was evident in all immunized animals. Wuhan-like D-D2 strain provides highly effective protection of hamsters against the development of productive infection and pneumonia when challenged both with ancestral virus and heterologous strains related to Delta (AY.122) and Omicron (sublineages BA.1.1 and BA.5.2) variants. Conclusion. SARS-CoV-2 attenuation is a promising strategy for the development of a highly effective nasal live COVID-19 vaccine.
- Published
- 2024
- Full Text
- View/download PDF
6. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
- Author
-
Han Li, Haoran Sun, Mengyan Tao, Qiqi Han, Haili Yu, Jiaqi Li, Xue Lu, Qi Tong, Juan Pu, Yipeng Sun, Litao Liu, Jinhua Liu, and Honglei Sun
- Subjects
- *
INFLUENZA A virus , *PARAINFLUENZA viruses , *AVIAN influenza A virus , *RECOMBINANT viruses , *INFLUENZA viruses , *HEMAGGLUTININ , *PANDEMIC preparedness - Abstract
The global circulation of clade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) in poultry and wild birds, increasing mammal infections, continues to pose a public health threat and may even form a pandemic. An efficacious vaccine against H5Ny HPAIVs is crucial for emergency use and pandemic preparedness. In this study, we developed a parainfluenza virus 5 (PIV5)-based vaccine candidate expressing hemagglutinin (HA) protein of clade 2.3.4.4b H5 HPAIV, termed rPIV5-H5, and evaluated its safety and efficacy in mice and ferrets. Our results demonstrated that intranasal immunization with a single dose of rPIV5-H5 could stimulate H5-specific antibody responses, moreover, a prime-boost regimen using rPIV5-H5 stimulated robust humoral, cellular, and mucosal immune responses in mice. Challenge study showed that rPIV5-H5 prime-boost regimen provided sterile immunity against lethal clade 2.3.4.4b H5N1 virus infection in mice and ferrets. Notably, rPIV5-H5 prime-boost regimen provided protection in mice against challenge with lethal doses of heterologous clades 2.2, 2.3.2, and 2.3.4 H5N1, and clade 2.3.4.4h H5N6 viruses. These results revealed that rPIV5-H5 can elicit protective immunity against a diverse clade of highly pathogenic H5Ny virus infection in mammals, highlighting the potential of rPIV5-H5 as a pan-H5 influenza vaccine candidate for emergency use. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Application of phosphorylcholine derivative as mucosal adjuvant enhancing mucosal immune responses in the upper respiratory tract.
- Author
-
Jimura, Tomohiro, Kurono, Yuichi, Hirano, Takashi, Kawabata, Masaki, and Yamashita, Masaru
- Subjects
- *
IMMUNE response , *CHOLERA toxin , *INTRANASAL administration , *OVUM , *IMMUNOGLOBULIN A - Abstract
A phosphorylcholine (PC)-derivative with high binding ability (PCDB) was intranasally administered to mice with ovalbumin (OVA), and immune responses were investigated to determine whether PCDB has antigenicity and adjuvanticity. BALB/c mice were intranasally immunized with PCDB coupled with OVA, unbound PCDB plus OVA, cholera toxin (CT) plus OVA, OVA alone, and PCDB alone. Then, the production of OVA- and PC-specific antibodies in external secretions and serum, and the secretion of cytokines such as IL-4 and IFN-γ from splenic mononuclear cells by stimulation with PCDB and OVA were examined. Furthermore, the secretion of IL-12p40 from CD11c+ cells following stimulation with PCDB was observed to clarify the adjuvant effect of PCDB through TLR4. Intranasal immunization with PCDB plus OVA increased OVA- and PC-specific IgA in external secretions and OVA- and PC-specific antibodies in the serum. The analysis of IgG subclasses specific to OVA and PC showed a higher production of IgG1 than IgG2, and the secretion of both IL-4 and IFN-γ was enhanced. However, IL-12p40 secretion from CD11c+ cells was increased and OVA-specific IgE production was not promoted by PCDB stimulation. Intranasal administration of the protein antigen with PCDB enhanced immune responses specific to the mixed antigen and PC. Although PCDB acted to bias the immune response toward the Th2-type, antigen-specific IgE production did not increase. These findings suggest that PCDB has the potential to be a mucosal vaccine with both adjuvanticity and antigenicity without causing side effects due to type I allergy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses
- Author
-
Li Chen, Wenyan Ren, Hong Lei, Jiayu Wang, Haiying Que, Dandan Wan, Aqu Alu, Dandan Peng, Minyang Fu, Weiqi Hong, Yuhe Huang, Xiangrong Song, Guangwen Lu, and Xiawei Wei
- Subjects
Heterologous immunization ,Intranasal immunization ,mRNA vaccine ,SARS-CoV-2 ,Subunit protein vaccine ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has decreased the efficacy of SARS-CoV-2 vaccines in containing coronavirus disease 2019 (COVID-19) over time, and booster vaccination strategies are urgently necessitated to achieve sufficient protection. Intranasal immunization can improve mucosal immunity, offering protection against the infection and sustaining the spread of SARS-CoV-2. In this study, an intranasal booster of the RBD-HR vaccine after two doses of the mRNA vaccine significantly increased the levels of specific binding antibodies in serum, nasal lavage fluid, and bronchoalveolar lavage fluid compared with only two doses of mRNA vaccine. After intranasal boosting with the RBD-HR vaccine, the levels of serum neutralizing antibodies against prototype and variant strains of SARS-CoV-2 pseudoviruses were markedly higher than those in mice receiving mRNA vaccine alone, and intranasal boosting with the RBD-HR vaccine also inhibited the binding of RBD to hACE2 receptors. Furthermore, the heterologous intranasal immunization regimen promoted extensive memory T cell responses and activated CD103+ dendritic cells in the respiratory mucosa, and potently enhanced the formation of T follicular helper cells and germinal center B cells in vital immune organs, including mediastinal lymph nodes, inguinal lymph nodes, and spleen. Collectively, these data infer that heterologous intranasal boosting with the RBD-HR vaccine elicited broad protective immunity against SARS-CoV-2 both locally and systemically.
- Published
- 2024
- Full Text
- View/download PDF
9. Intranasal Immunization with a Recombinant Adenovirus Encoding Multi-Stage Antigens of Mycobacterium tuberculosis Preferentially Elicited CD8+ T Cell Immunity and Conferred a Superior Protection in the Lungs of Mice than Bacillus Calmette–Guerin
- Author
-
Limei Wang, Jian Kang, and Hong Jiang
- Subjects
tuberculosis ,Mycobacterium tuberculosis ,vaccine ,recombinant adenovirus ,intranasal immunization ,multi-stage antigens ,Medicine - Abstract
The development of a tuberculosis (TB) vaccine is imperative. Employing multi-stage Mycobacterium tuberculosis (Mtb) antigens as targeted antigens represents a critical strategy in establishing an effective novel TB vaccine. In this investigation, we evaluated the immunogenicity and protective efficacy of a recombinant adenovirus vaccine expressing two fusion proteins, Ag85B-ESAT6 (AE) and Rv2031c-Rv2626c (R2), derived from multi-stage antigens of Mtb via intranasal administration in mice. Intranasal delivery of Ad-AE-R2 induced both long-lasting mucosal and systemic immunities, with a preferential elicitation of CD8+ T cell immunity demonstrated by the accumulation and retention of CD8+ T cells in BALF, lung, and spleen, as well as the generation of CD8+ TRM cells in BALF and lung tissues. Compared to subcutaneous immunization with Bacillus Calmette-Guerin (BCG), Ad-AE-R2 provided superior protection against high-dose intratracheal BCG challenge, specifically within the lungs of mice. Our findings support the notion that empowering T cells within the respiratory mucosa is crucial for TB vaccine development while highlighting targeting CD8+ T cell immunity as an effective strategy for optimizing TB vaccines and emphasizing that eliciting systemic memory immunity is also vital for the successful development of a TB mucosal vaccine. Furthermore, our results demonstrate that the BCG challenge serves as a convenient and efficient method to evaluate candidate vaccine efficacy.
- Published
- 2024
- Full Text
- View/download PDF
10. Characterization of protective immune responses against Neisseria gonorrhoeae induced by intranasal immunization with adhesion and penetration protein
- Author
-
Lingyin Xia, Qin Lu, Xiaosu Wang, Chengyi Jia, Yujie Zhao, Guangli Wang, Jianru Yang, Ningqing Zhang, Xun Min, Jian Huang, and Meirong Huang
- Subjects
Neisseria gonorrhoeae ,Adhesion and penetration protein ,Intranasal immunization ,Opsonophagocytic activity ,Bactericidal activity ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Drug-resistant N. gonorrhoeae is an urgent threat to global public health, and vaccine development is the best long-term strategy for controlling gonorrhea. We have previously shown that adhesion and penetration protein (App) play a role in the adhesion, invasion, and reproductive tract colonization of N. gonorrhoeae. Here, we describe the immune response induced by intranasal immunization with passenger and translocator fragments of App. The recombinant App passenger and translocator fragments induced high titers of IgG and IgA antibodies in serum and vaginal washes. Antibodies produced by App passenger and the combination of passenger and translocator mediated the killing of N. gonorrhoeae via serum bactericidal activity and opsonophagocytic activity, whereas antisera from translocator-immunized groups had lower bactericidal activity and opsonophagocytic activity. The antisera of the App passenger and translocator, alone and in combination, inhibited the adhesion of N. gonorrhoeae to cervical epithelial cells in a concentration-dependent manner. Nasal immunization with App passenger and translocator fragments alone or in combination induced high levels of IgG1, IgG2a, and IgG2b antibodies and stimulated mouse splenocytes to secrete cytokines IFN-γ and IL-17A, suggesting that Th1 and Th17 cellular immune responses were activated. In vivo experiments have shown that immune App passenger and transporter fragments can accelerate the clearance of N. gonorrhoeae in the vagina of mice. These data suggest that the App protein is a promising N. gonorrhoeae vaccine antigen.
- Published
- 2024
- Full Text
- View/download PDF
11. A novel simian adenovirus-vectored COVID-19 vaccine elicits effective mucosal and systemic immunity in mice by intranasal and intramuscular vaccination regimens
- Author
-
Panli Zhang, Shengxue Luo, Peng Zou, Qitao Deng, Cong Wang, Jinfeng Li, Peiqiao Cai, Ling Zhang, Chengyao Li, and Tingting Li
- Subjects
adenoviral vector ,intranasal immunization ,mucosal immunity ,respiratory virus ,vaccination regimen ,Microbiology ,QR1-502 - Abstract
ABSTRACT The failure of COVID-19 vaccines to prevent SARS-CoV-2 infection and transmission, a possibly critical reason was the lack of protective mucosal immunity in the respiratory tract. Here, we evaluated the effects of mucosal and systemic immunity from a novel simian adenovirus-vectored COVID-19 vaccine (Sad23L-nCoV-S) in mice in comparison with Ad5-nCoV-S by intranasal (IN) drip and intramuscular (IM) injection vaccinations. As good as the well-known Ad5-nCoV-S vaccine, a single-dose IN inoculation of 1 × 109 PFU Sad23L-nCoV-S vaccine induced a similar level of IgG S-binding antibody (S-BAb) and neutralizing antibody (NAb) and higher IgA in serum, while IN route raised significantly higher IgG and IgA S-BAb and NAb in bronchoalveolar lavage (BAL), and specific IFN-γ secreting T-cell response in lung compared with IM route, but lower T-cell response in spleen. By prime-boost vaccination regimens with different combinations of IN and IM inoculations of Sad23L-nCoV-S vaccine, the IN-involved vaccination stimulated higher protective mucosal or local immunity in BAL and lung, while the IM-involved immunization induced higher systemic immunity in serum and spleen. A long-term sustained mucosal and systemic NAb and T- cell immunity to SARS-CoV-2 was maintained at high level over 32 weeks by prime-boost vaccination regimens with IN and IM routes. In conclusion, priming or boosting immunization with IN inoculation of Sad23L-nCoV-S vaccine could induce effective mucosal immunity and in combination of IM route could additionally achieve systemic immunity, which provided an important reference for vaccination regimens against respiratory virus infection. IMPORTANCE The essential goal of vaccination is to generate potent and long-term protection against diseases. Several factors including vaccine vector, delivery route, and boosting regimen influence the outcome of prime-boost immunization approaches. The immunization regimens by constructing a novel simian adenovirus-vectored COVID-19 vaccine and employing combination of intranasal and intramuscular inoculations could elicit mucosal neutralizing antibodies against five mutant strains in the respiratory tract and strong systemic immunity. Immune protection could last for more than 32 weeks. Vectored vaccine construction and immunization regimens have positively impacted respiratory disease prevention.
- Published
- 2023
- Full Text
- View/download PDF
12. Immunization with Multiple Virulence Factors Provides Maternal and Neonatal Protection against Group B Streptococcus Serotypes.
- Author
-
Wang, Jie, Li, Wenbo, Li, Ning, and Wang, Beinan
- Subjects
STREPTOCOCCUS agalactiae ,NEONATAL infections ,VACCINE effectiveness ,SEROTYPES ,IMMUNIZATION ,UREAPLASMA - Abstract
Group B streptococcus (GBS) commonly colonizes the vaginal tract and is a leading cause of life-threatening neonatal infections and adverse pregnancy outcomes. No effective vaccine is clinically available. Conserved bacterial virulence factors, including those of GBS, have been employed as vaccine components. We investigated serotype-independent protection against GBS by intranasal immunization with six conserved GBS virulence factors (GBSV6). GBSV6 induced systemic and vaginal antibodies and T cell responses in mice. The immunity reduced mouse mortality and vaginal colonization by various GBS serotypes and protected newborn mice of immunized dams against GBS challenge. Intranasal GBSV6 immunization also provided long-lasting protective immunity and had advantages over intramuscular GBSV6 immunization regarding restricting vaginal GBS colonization. Our findings indicate that intranasal immunization targeting multiple conserved GBS virulence factors induces serotype-independent immunity, which protects against GBS infection systemically and vaginally in dams and prevents newborn death. The study presents valuable strategies for GBS vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. A rational strategy for the maintenance of antiviral immunity to new SARS-CoV-2 strains
- Author
-
Vladimir P. Baklaushev, Gaukhar M. Yusubalieva, Mikhail V. Bychinin, Saule M. Yusubalieva, Vladimir A. Kalsin, and Aleksandr V. Troitskiy
- Subjects
covid-19 ,sars-cov-2 ,omicron ba.1, ba.2, ba.4, ba.5, ba.2.75 ,neutralizing antibodies ,mucosal immune response ,intranasal immunization ,nasal vaccines ,next-generation vaccines ,Medicine - Abstract
New variants of SARS-CoV-2 such as Omicron BA.2, BA.4/5, BA.2.12.1 and BA 2.75 are characterized by higher infectivity and the ability to escape virus-neutralizing antibodies against previous coronavirus variants. The S-trimer of BA.2 and its phylogenetic derivatives are characterized by a predominant Up-conformation, which facilitates the interaction with ACE2 on target cells and promotes the resistance to neutralizing antibodies. The immunity acquired from the infection with earlier strains is non-sterile for both early and later strains; the booster systemic immunization does not significantly affect the effectiveness of antiviral immunity, and its feasibility is currently being questioned. Studies of the mucosal immune response have shown that intranasal immunization with adenovirus vaccines provides more pronounced protective immunity than systemic reimmunization does. A promising approach is the creation of multivalent inhaled next generation vaccines containing immunoadjuvants that activate B- and T-cell mucosal immunity. Currently, a large number of intranasal vaccines are undergoing phase I/II trials, while the preclinical and preliminary clinical results indicate that this method of vaccination provides a better mucosal immune response at the entry site of the virus than systemic immunization does. This strategy may provide a long-term immune protection against the currently existing and yet unknown new strains of SARS-CoV-2.
- Published
- 2022
- Full Text
- View/download PDF
14. Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus
- Author
-
Yufei Zhang, Li Yang, Jiali Zhang, Kun Huang, Xiaomei Sun, Ying Yang, Ting Wang, Qiang Zhang, Zhong Zou, and Meilin Jin
- Subjects
Swine Influenza A virus ,Lactobacillus plantarum ,Mucosal immunity ,Intranasal immunization ,Oral immunization ,Microbiology ,QR1-502 - Abstract
Abstract Background Swine influenza A virus (swIAV) is a major concern for the swine industry owing to its highly contagious nature and acute viral disease. Currently, most commercial swIAV vaccines are traditional inactivated virus vaccines. The Lactobacillus plantarum-based vaccine platform is a promising approach for mucosal vaccine development. Oral and intranasal immunisations have the potential to induce a mucosal immune response, which confers protective immunity. The aim of this study was to evaluate the probiotic potential and adhesion ability of three L. plantarum strains. Furthermore, a recombinant L. plantarum strain expressing the head domain of swIAV antigen HA1 was constructed and evaluated for its ability to prevent swIAV infection. Results The three L. plantarum strains isolated from healthy pig faecal samples maintained the highest survival rate when incubated at pH 3 and at bile salt concentration of 0.3%. They also showed high adherence to intestinal cells. All three L. plantarum strains were monitored in live mice, and no major differences in transit time were observed. Recombinant L. plantarum expressed swIAV HA1 protein (pSIP401-HA1-ZN-3) and conferred effective mucosal, cellular and systemic immune responses in the intestine as well as in the upper respiratory airways of mice. In conclusion, the oral and intranasal administration of L. plantarum strain pSIP401-HA1-ZN-3 in mice induced mucosal immunity and most importantly, provided protection against lethal influenza virus challenge. Conclusion In summary, these findings suggest that the engineered L. plantarum strain pSIP401-HA1-ZN-3 can be considered as an alternative approach for developing a novel vaccine during an swine influenza A pandemic.
- Published
- 2022
- Full Text
- View/download PDF
15. A glycoprotein E gene-deleted bovine alphaherpesvirus 1 strain is attenuated and immunogenic for calves with passive immunity upon intranasal immunization.
- Author
-
Merchioratto, Ingryd, Junior Roman, Isac, Hettwer Pedroso, Natália, Britto de Oliveira, Pablo Sebastian, Joaquim Silva Júnior, José Valter, Weiblen, Rudi, and Furtado Flores, Eduardo
- Subjects
- *
CALVES , *VACCINE effectiveness , *IMMUNE response , *IMMUNIZATION , *BOS , *VACCINATION status , *VIRAL vaccines , *IMMUNITY , *BOVINE viral diarrhea virus - Abstract
Vaccination has been used to prevent the losses associated with Bovine alphaherpesvirus 1 (BoHV-1) infection but passively acquired antibodies may compromise vaccine efficacy. Intranasal immunization (IN) of calves with modified live viral BoHV-1 vaccines has proven to overcome the acquired passive antibodies and confer adequate protection. Herein, we evaluated the safety and immunogenicity of a glycoprotein E-deleted Brazilian BoHV-1 strain (BoHV-1gEΔ) for IN immunization of calves. Ten 1-to-2 months-old calves with virusneutralizing titers (VN) ranging from 2-64 were immunized IN with viable BoHV-1gEΔ (107.1 TCID50) and four remained as unvaccinated controls (VN titers 8-32). After IN immunization, calves presented a transient (2-6 days) mild nasal secretion and shed the vaccine virus in nasal secretions in low titers (<102.6TCID50/mL) for 4-8 days. Interestingly, the vaccinated calves did not show an increase in VN titers after vaccination. Rather, they presented a gradual reduction in serum VN antibodies in the following weeks - similarly to unvaccinated controls. Upon IN challenge with a virulent heterologous BoHV-1 strain at day 55 post-immunization (107.63TCID50), vaccinated calves shed significantly less virus from day 6 post-challenge onwards (p < 0.07) and for a shorter period of time than the controls (p < 0.0024). Importantly, both the duration and intensity of clinical signs were reduced in vaccinated animals. In addition, vaccinated calves showed an abrupt raise in VN titers post-challenge, indicating adequate immunological priming by vaccination. In summary, immunization of calves harboring passive antibodies with BoHV-1gEΔ by the IN route was able to prime the immunity to afford partial virological and clinical protection upon challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Cross-Protection against Acute Staphylococcus aureus Lung Infection in Mice by a D-Glutamate Auxotrophic Vaccine Candidate.
- Author
-
García, Patricia, Cabral, Maria P., Beceiro, Alejandro, Moscoso, Miriam, and Bou, Germán
- Subjects
STAPHYLOCOCCUS aureus infections ,LUNG infections ,VACCINES ,STAPHYLOCOCCUS aureus ,VACCINE development - Abstract
Staphylococcus aureus is regarded as a threatening bacterial pathogen causing invasive pneumonia in healthcare settings and in the community. The continuous emergence of multidrug resistant strains is narrowing the treatment options for these infections. The development of an effective S. aureus vaccine is, therefore, a global priority. We have previously developed a vaccine candidate, 132 ΔmurI Δdat, which is auxotrophic for D-glutamate, and protects against sepsis caused by S. aureus. In the present study, we explored the potential of this vaccine candidate to prevent staphylococcal pneumonia, by using an acute lung infection model in BALB/c mice. Intranasal inoculation of the vaccine strain yielded transitory colonization of the lung tissue, stimulated production of relevant serum IgG and secretory IgA antibodies in the lung and distal vaginal mucosa and conferred cross-protection to acute pneumonia caused by clinically important S. aureus strains. Although these findings are promising, additional research is needed to minimize dose-dependent toxicity for safer intranasal immunization with this vaccine candidate. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. The relationship between the chemical structure, physicochemical properties, and mucosal adjuvanticity of sugar-based surfactants.
- Author
-
Kawamura, Hanae, Yoshino, Naoto, Murakami, Kazuyuki, Kawamura, Hideki, Sugiyama, Ikumi, Sasaki, Yutaka, Odagiri, Takashi, Sadzuka, Yasuyuki, and Muraki, Yasushi
- Subjects
- *
CHEMICAL structure , *CRITICAL micelle concentration , *SURFACE active agents , *ANTIBODY titer - Abstract
[Display omitted] The relationship between the chemical structure, physicochemical properties, and mucosal adjuvanticity of sugar-based surfactants (SBSs) has not been sufficiently elucidated. Thus, in the present study, we systematically analyzed 11 SBSs for mucosal adjuvanticity. Ovalbumin (OVA)-specific antibody titers were measured in mice immunized intranasally with OVA plus SBS. We found that four SBSs (trehalose monododecanoate, sucrose monododecanoate, n -dodecyl-α- d -maltopyranoside, and n -dodecyl-β- d -maltopyranoside) exhibited the most potent adjuvanticity. We identified the following associations between chemical structure and adjuvanticity: 1) OVA-specific antibody titer increased with an increasing number of carbon atoms in the alkyl chain; 2) the adjuvanticity was not affected by the type of sugar or bond between the sugar and alkyl chain; and 3) SBSs with rigid structures exhibited less adjuvanticity. The relationship between physicochemical properties and adjuvanticity was as follows: 1) SBSs exhibited adjuvanticity above the critical micelle concentration and 2) in the SBSs with potent adjuvanticity, the diameter of the SBS-OVA complex was 70–75 nm. Our study indicates evidence for the direct involvement of chemical structure and physicochemical properties in determining adjuvanticity in SBSs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. The protective immunity induced by intranasally inoculated serotype 63 chimpanzee adenovirus vector expressing human respiratory syncytial virus prefusion fusion glycoprotein in BALB/c mice.
- Author
-
Lei Huang, Mei-Qing Liu, Chang-Qing Wan, Ning-Ning Cheng, Yan-Bin Su, Yan-Peng Zheng, Xiang-Lei Peng, Jie-Mei Yu, Yuan-Hui Fu, and Jin-Sheng He
- Subjects
RESPIRATORY syncytial virus ,ADENOVIRUSES ,MICE ,CHIMPANZEES ,VACCINATION ,RESPIRATORY diseases ,IMMUNITY ,T cells ,GENETIC code - Abstract
Human respiratory syncytial virus (RSV) is a ubiquitous pediatric pathogen causing serious lower respiratory tract disease worldwide. No licensed vaccine is currently available. In this work, the coding gene for mDS-Dav1, the fulllength and prefusion conformation RSV fusion glycoprotein (F), was designed by introducing the stabilized prefusion F (preF) mutations from DS-Cav1 into the encoding gene of wild-type RSV (wtRSV) F protein. The recombinant adenovirus encoding mDS-Cav1, rChAd63-mDS-Cav1, was constructed based on serotype 63 chimpanzee adenovirus vector and characterized in vitro. After immunizing mice via intranasal route, the rChAd63-mDS-Cav1 induced enhanced neutralizing antibody and F-specific CD8+ T cell responses as well as good immune protection against RSV challenge with the absence of enhanced RSV disease (ERD) in BALB/c mice. The results indicate that rChAd63-mDS-Cav1 is a promising mucosal vaccine candidate against RSV infection and warrants further development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice.
- Author
-
Ren, Hu, Li, Hai, Cao, Lei, Wang, Zhan, Zhou, Yangzi, Guo, Jinyuan, Zhang, Yan, Liu, Hongtu, and Xu, Wenbo
- Subjects
- *
VACCINE trials , *RESPIRATORY syncytial virus , *OLDER people , *INTRANASAL administration , *MICE , *IMMUNOGLOBULINS , *RESPIRATORY infections , *PARAINFLUENZA viruses - Abstract
Human respiratory syncytial virus (HRSV) is a leading cause of lower respiratory tract infections in elderly individuals and young children/infants and can cause bronchiolitis and even death. There is no licensed HRSV vaccine. An ideal vaccine should induce high titers of neutralizing antibodies and a Th1-biased immune response. In this study, we used EXPI293 cells to express the fusion (F) protein with a prefusion conformation (PrF) and compared the safety and efficacy of intranasal immunization with PrF in combination with two mucosal adjuvants (CpG ODN and liposomes) in mice. After two intranasal administrations, mice in the PrF + CpG group produced high titers of neutralizing antibodies (4961) and a Th1-biased immune response compared with the PrF + Lipo group. The lung viral load of mice in the PrF + CpG group was significantly reduced (3.5 log) compared with that in the adjuvant control group, and the survival rate was 100 %, while the survival rate of mice in the PrF + Lipo group was only 67 %. At the same time, this immunization strategy reduced the pathological damage to the lungs in mice. In conclusion, the combination of PrF and CpG adjuvant is immunogenic, elicits a Th1 type immune response, and completely protects mice from a lethal HRSV challenge. It is worthy of further evaluation as an HRSV vaccine in clinical trials. Clinical trial registration. This study was not related to human participation or experimentation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Improved cellular immune response induced by intranasal boost immunization with chitosan coated DNA vaccine against H9N2 influenza virus challenge.
- Author
-
Zhang, Tongyu, Tian, Yawen, Zhang, Xiao, Wang, Wenfeng, He, Yingkai, Ge, Chongbo, Jia, Futing, Wang, Zhannan, and Jiang, Yanlong
- Subjects
- *
AVIAN influenza A virus , *DNA vaccines , *ORAL drug administration , *AVIAN influenza , *ORAL vaccines , *VIRAL shedding - Abstract
The H9N2 avian influenza virus (AIV) is spreading worldwide. Presence of H9N2 virus tends to increase the chances of infection with other pathogens which can lead to more serious economic losses. In a previous study, a regulated delayed lysis Salmonella vector was used to deliver a DNA vaccine named pYL233 encoding M1 protein, mosaic HA protein and chicken GM-CSF adjuvant. To further increase its efficiency, chitosan as a natural adjuvant was applied in this study. The purified plasmid pYL233 was coated with chitosan to form a DNA containing nanoparticles (named CS233) by ionic gel method and immunized by intranasal boost immunization in birds primed by oral administration with Salmonella strain. The CS233 DNA nanoparticle has a particle size of about 150 nm, with an encapsulation efficiency of 93.2 ± 0.12 % which protected the DNA plasmid from DNase I digestion and could be stable for a period of time at 37°. After intranasal boost immunization, the CS233 immunized chickens elicited higher antibody response, elevated CD4+ T cells and CD8+ T cells activation and increased T-lymphocyte proliferation, as well as increased productions of IL-4 and IFN-γ. After challenge, chickens immunized with CS233 resulted in the lowest levels of pulmonary virus titer and viral shedding as compared to the other challenge groups. The results showed that the combination of intranasal immunization with chitosan-coated DNA vaccine and oral immunization with regulatory delayed lytic Salmonella strain could enhance the immune response and able to provide protection against H9N2 challenge. • The chitosan-coated DNA vaccine was effectively alleviate the H9N2 influenza virus challenge in egg-laying chickens. • The chitosan-coated DNA vaccine could improve cellular immune response induced by H9N2 influenza virus challenge. • The chitosan-coated DNA vaccine could induce higher antibody responses through intranasal immunization. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.
- Author
-
Xu, Yongru, Sun, Fang, Chuai, Zhengran, Wang, Junyun, Bai, Zhifang, Bian, Chengrong, Wang, Xiliang, Zhao, Zhongpeng, Liu, Yongzhuang, and Yang, Penghui
- Subjects
- *
RESPIRATORY syncytial virus infections , *RESPIRATORY syncytial virus , *INFLUENZA vaccines , *RESPIRATORY syncytial virus infection vaccines , *VIRUS diseases - Abstract
Respiratory syncytial virus is the major cause of respiratory viral infections, particularly in infants, immunocompromised populations, and the elderly (over 65 years old), the prevention of RSV infection has become a priority. In this study, we generated a chimeric influenza virus, termed LAIV/RSV/HA-3F, using reverse genetics technology which contained three repeats of the RSV fusion protein neutralizing epitope site II to the N terminal in the background of the hemagglutinin (HA) gene of cold adapted influenza vaccine A/California/7/2009 ca. LAIV/RSV/HA-3F exhibited cold-adapted (ca) and attenuated (att) phenotype. BALB/c mice immunized intranasally with LAIV/RSV/HA-3F showed robust immunogenicity, inducing viral-specific antibody responses against both influenza and RSV, eliciting RSV-specific humoral, cellular and mucosal immune responses. LAIV/RSV/HA-3F also conferred protection as indicated by reduced viral titers and improved lung histopathological alterations against live RSV virus challenge. Mechanismly, single-cell RNA sequencing (scRNA-seq) and single-cell T cell antigen receptor (TCR) sequencing were employed to characterize the immune responses triggered by chimeric RSV vaccine, displaying that LAIV/RSV/HA-3F provided protection mainly via interferon-γ (IFN-γ). Moreover, we found that LAIV/RSV/HA-3F significantly inhibited viral replication in the challenged lung and protected against subsequent RSV challenge in cotton rats without causing lung disease. Taken together, our findings demonstrated that LAIV/RSV/HA-3F has potential as a promising bivalent vaccine with dual purpose candidate for the prevention of influenza and RSV, and preclinical and clinical studies warrant further investigations. • We generated a chimeric influenza virus LAIV/RSV/HA-3F carrying three repeats of RSV F neutralizing epitope site II. • LAIV/RSV/HA-3F elicited vigorous humoral, cellular and mucosal immune responses. • LAIV/RSV/HA-3F protected BALB/c mice and cotton rats from RSV infection without causing ERD. • LAIV/RSV/HA-3F provided protection mainly depended on IFN-γ signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Immunization with Multiple Virulence Factors Provides Maternal and Neonatal Protection against Group B Streptococcus Serotypes
- Author
-
Jie Wang, Wenbo Li, Ning Li, and Beinan Wang
- Subjects
group B streptococcus ,virulence factors ,intranasal immunization ,vaginal colonization ,maternal vaccines ,Medicine - Abstract
Group B streptococcus (GBS) commonly colonizes the vaginal tract and is a leading cause of life-threatening neonatal infections and adverse pregnancy outcomes. No effective vaccine is clinically available. Conserved bacterial virulence factors, including those of GBS, have been employed as vaccine components. We investigated serotype-independent protection against GBS by intranasal immunization with six conserved GBS virulence factors (GBSV6). GBSV6 induced systemic and vaginal antibodies and T cell responses in mice. The immunity reduced mouse mortality and vaginal colonization by various GBS serotypes and protected newborn mice of immunized dams against GBS challenge. Intranasal GBSV6 immunization also provided long-lasting protective immunity and had advantages over intramuscular GBSV6 immunization regarding restricting vaginal GBS colonization. Our findings indicate that intranasal immunization targeting multiple conserved GBS virulence factors induces serotype-independent immunity, which protects against GBS infection systemically and vaginally in dams and prevents newborn death. The study presents valuable strategies for GBS vaccine development.
- Published
- 2023
- Full Text
- View/download PDF
23. Double Auxotrophy to Improve the Safety of a Live Anti- Pseudomonas aeruginosa Vaccine.
- Author
-
Fuentes-Valverde, Víctor, García, Patricia, Moscoso, Miriam, and Bou, Germán
- Subjects
PSEUDOMONAS aeruginosa ,AUXOTROPHY ,RESPIRATORY infections ,VACCINES ,VACCINE safety - Abstract
Pseudomonas aeruginosa is an opportunistic nosocomial pathogen that causes serious infections in the respiratory tract of immunocompromised or critically ill patients, and it is also a significant source of bacteremia. Treatment of these infections can be complicated due to the emergence of multidrug-resistant P. aeruginosa strains worldwide. Hence, the development of prophylactic vaccines is a priority for at-risk patients. We have previously developed a vaccine candidate with a single auxotrophy for D-glutamate, PAO1 ΔmurI, which protects against sepsis and acute pneumonia caused by P. aeruginosa. Given the paramount importance of safety in the development of live attenuated vaccines, we have improved the safety of the vaccine candidate by reducing the probability of a reversion to virulence by the inclusion of an additional auxotrophy for D-alanine. Single and double auxotrophs behaved in a similar manner in relation to the attenuation level, immunogenicity and protective efficacy, but the double auxotroph has the advantage of being more stable and safer as a candidate vaccine against respiratory infections caused by P. aeruginosa. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus.
- Author
-
Zhang, Yufei, Yang, Li, Zhang, Jiali, Huang, Kun, Sun, Xiaomei, Yang, Ying, Wang, Ting, Zhang, Qiang, Zou, Zhong, and Jin, Meilin
- Subjects
- *
SWINE influenza , *INFLUENZA A virus, H1N1 subtype , *INFLUENZA A virus , *LACTOBACILLUS plantarum , *INFLUENZA viruses , *INFLUENZA , *VIRUS diseases , *H1N1 influenza - Abstract
Background: Swine influenza A virus (swIAV) is a major concern for the swine industry owing to its highly contagious nature and acute viral disease. Currently, most commercial swIAV vaccines are traditional inactivated virus vaccines. The Lactobacillus plantarum-based vaccine platform is a promising approach for mucosal vaccine development. Oral and intranasal immunisations have the potential to induce a mucosal immune response, which confers protective immunity. The aim of this study was to evaluate the probiotic potential and adhesion ability of three L. plantarum strains. Furthermore, a recombinant L. plantarum strain expressing the head domain of swIAV antigen HA1 was constructed and evaluated for its ability to prevent swIAV infection. Results: The three L. plantarum strains isolated from healthy pig faecal samples maintained the highest survival rate when incubated at pH 3 and at bile salt concentration of 0.3%. They also showed high adherence to intestinal cells. All three L. plantarum strains were monitored in live mice, and no major differences in transit time were observed. Recombinant L. plantarum expressed swIAV HA1 protein (pSIP401-HA1-ZN-3) and conferred effective mucosal, cellular and systemic immune responses in the intestine as well as in the upper respiratory airways of mice. In conclusion, the oral and intranasal administration of L. plantarum strain pSIP401-HA1-ZN-3 in mice induced mucosal immunity and most importantly, provided protection against lethal influenza virus challenge. Conclusion: In summary, these findings suggest that the engineered L. plantarum strain pSIP401-HA1-ZN-3 can be considered as an alternative approach for developing a novel vaccine during an swine influenza A pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Comparison of the efficacy and safety of different immunization routes induced by human respiratory syncytial virus F protein with CpG adjuvant in mice.
- Author
-
Li, Hai, Ren, Hu, Cao, Lei, Guo, Jinyuan, Zhang, Yan, Fang, Qiongqiong, and Xu, Wenbo
- Subjects
- *
RESPIRATORY syncytial virus , *VIRAL proteins , *IMMUNIZATION , *SAFETY , *ANTIBODY titer , *MICE , *VACCINES - Abstract
Human respiratory syncytial virus (HRSV) is a leading cause worldwide of severe respiratory illness in infants and the elderly. The ideal HRSV vaccine should induce a systemic immune response, especially mucosal immunity. In this study, mice were immunized twice with F protein combined with CpG adjuvant to compare the safety and efficacy of 4 immunization routes, including intranasal primed/intramuscular boosted immunization (CpG + F/in+im), intramuscular primed/intranasal boosted immunization (CpG + F/im+in), intramuscular primed/intramuscular boosted immunization (CpG + F/im + im) and intranasal primed/intranasal boosted immunization (CpG + F/in+in). Compared with the control group (CpG/in+im, CpG/im+in, CpG/im + im and CpG/in+in), all 4 immunization routes induced a high titer of neutralizing antibodies and a strong cellular immune response. Mice in the CpG + F/in+in group induced the highest antibody neutralization titer, and IgA antibody in bronchoalveolar lavage fluid (BALF) was the highest. The copy of HRSVs in the lung decreased by approximately 3 log10. As seen from the IgG1/IgG2a and IFN-γ/IL-4-secreting lymphocyte ratios, compared with the mice in the CpG + F/im + im group, mice in the CpG + F/in+in group induced Th1-baised humoral and cellular immune responses and significantly reduced lung pathological injury. In conclusion, among the 4 immunization routes, the safety and efficacy induced by the mice in the CpG + F/in+in group were the best. We can conclude that intranasal immunization is superior to intramuscular immunization using F protein with CpG adjuvant as vaccine candidates. • Intranasal immunization is superior to intramuscular immunization using F protein with CpG adjuvant. • Intranasal primed/intranasal boosted immunization elicited mucosal and systemic immune responses in mice. • The safety and efficacy induced by the mice in the CpG+F/in+in group were the best. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Intranasal delivery of a recombinant adenovirus vaccine encoding the PEDV COE elicits potent mucosal and systemic antibody responses in mice.
- Author
-
Yan S, Luo Y, Zhan N, Xu H, Yao Y, Liu X, Dong X, Kang L, Zhang G, and Liu P
- Subjects
- Animals, Mice, Swine, Female, Viral Vaccines immunology, Viral Vaccines administration & dosage, Viral Vaccines genetics, Coronavirus Infections prevention & control, Coronavirus Infections immunology, Coronavirus Infections veterinary, Adenoviridae genetics, Adenoviridae immunology, Humans, Swine Diseases prevention & control, Swine Diseases immunology, Swine Diseases virology, Antibody Formation immunology, Immunoglobulin A, Genetic Vectors genetics, Porcine epidemic diarrhea virus immunology, Porcine epidemic diarrhea virus genetics, Mice, Inbred BALB C, Administration, Intranasal, Immunity, Mucosal, Antibodies, Viral blood, Antibodies, Viral immunology, Antibodies, Neutralizing immunology, Antibodies, Neutralizing blood, Vaccines, Synthetic immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics
- Abstract
Porcine epidemic diarrhea virus (PEDV) is an enteropathogenic coronavirus that causes substantial economic loss to the global pig industry. The emergence of PEDV variants has increased the need for new vaccines, as commercial vaccines confer inferior protection against currently circulating strains. It is well established that the induction of mucosal immunity is crucial for PEDV vaccines to provide better protection against PEDV infection. In this study, we constructed a recombinant adenovirus expressing the core neutralization epitope (COE) of G2b PEDV based on human adenovirus serotype 5 (Ad5). We evaluated the effects of different administration routes and doses of vaccine immunogenicity in Balb/c mice. Both intramuscular (IM) and intranasal (IN) administration elicited significant humoral responses, including COE-specific IgG in serum and mucosal secretions, along with serum-neutralizing antibodies. Moreover, IN delivery was more potent than IM in stimulating IgA in serum and mucosal samples and in dampening the immune response to the Ad5 vector. The immune response was stronger after high versus low dose IM injection, whereas no significant difference was observed between high and low IN doses. In summary, our findings provide important insights for developing novel PEDV vaccines.IMPORTANCEPorcine epidemic diarrhea (PED) is a highly contagious disease that has severe economic implications for the pork industry. Developing an effective vaccine against PEDV remains a necessity. Here, we generated a recombinant adenovirus vaccine based on Ad5 to express the COE protein of PEDV (rAd5-PEDV-COE) and systematically evaluated the immunogenicity of the adenovirus-vectored vaccine using different administration routes (intramuscular and intranasal) and doses in a mouse model. Our results show that rAd5-PEDV-COE induced potent systemic humoral response regardless of the dose or immunization route. Notably, intranasal delivery was superior to induce peripheral and mucosal IgA antibodies compared with intramuscular injection. Our data provide valuable insights into designing novel PEDV vaccines., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
27. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
- Author
-
Ramasamy, Ranjan
- Subjects
- *
IMMUNE response , *SARS-CoV-2 , *NASAL mucosa , *INTRANASAL administration , *COVID-19 vaccines , *DENDRITIC cells - Abstract
Increasing evidence shows the nasal epithelium to be the initial site of SARS-CoV-2 infection, and that early and effective immune responses in the upper respiratory tract (URT) limit and eliminate the infection in the URT, thereby preventing infection of the lower respiratory tract and the development of severe COVID-19. SARS-CoV-2 interferes with innate immunity signaling and evolves mutants that can reduce antibody-mediated immunity in the URT. Recent genetic and immunological advances in understanding innate immunity to SARS-CoV-2 in the URT, and the ability of prior infections as well as currently available injectable and potential intranasal COVID-19 vaccines to generate anamnestic adaptive immunity in the URT, are reviewed. It is suggested that the more detailed investigation of URT immune responses to all types of COVID-19 vaccines, and the development of safe and effective COVID-19 vaccines for intranasal administration, are important needs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges.
- Author
-
Chen, Chi-Hsun, Chen, Chung-Chu, Wang, Wei-Bo, Lionel, Vania, Liu, Chia-Chyi, Huang, Li-Min, and Wu, Suh-Chin
- Subjects
- *
CHIMERIC proteins , *ZIKA virus , *IMMUNE response , *VIRAL envelope proteins , *FLAGELLIN , *ESCHERICHIA coli , *IMMUNOGLOBULINS - Abstract
Zika virus (ZIKV) infections in humans are mainly transmitted by the mosquito vectors, but human-to-human sexual transmission is also another important route. Developing a ZIKV mucosal vaccine that can elicit both systemic and mucosal immune responses is of particular interest. In this study, we constructed a recombinant ZIKV envelope DIII (ZDIII) protein genetically fused with Salmonella typhimurium flagellin (FliC-ZDIII) as a novel mucosal antigen for intranasal immunization. The results indicated that the FliC-ZDIII fusion proteins formulated with E. coli heat-labile enterotoxin B subunit (LTIIb-B5) adjuvant greatly increased the ZDIII-specific IgG, IgA, and neutralizing titers in sera, and the ZDIII-specific IgA titers in bronchoalveolar lavage and vaginal fluids. Protective immunity was further assessed by subcutaneous and intravaginal ZIKV challenges. The second-generation FliCΔD3-2ZDIII was shown to result in a reduced titer of anti-FliC IgG antibodies in sera and still retained the same levels of serum IgG, IgA, and neutralizing antibodies and mucosal IgA antibodies without compromising the vaccine antigenicity. Therefore, intranasal immunization with FliCΔD3-2ZDIII fusion proteins formulated with LTIIb-B5 adjuvant elicited the greatest protective immunity against subcutaneous and intravaginal ZIKV challenges. Our findings indicated that the combination of FliCΔD3-2ZDIII fusion proteins and LTIIb-B5 adjuvant for intranasal immunization can be used for developing ZIKV mucosal vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Intranasal immunization with CPAF combined with cyclic-di-AMP induces a memory CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.
- Abstract
A preprint abstract from biorxiv.org discusses the urgent need for a vaccine against Chlamydia trachomatis, the most common bacterial sexually transmitted infection globally. The study focuses on the use of Chlamydial Protease Activity Factor (CPAF) as a vaccine candidate and the need for effective mucosal adjuvants to induce protective cell-mediated immunity. The researchers found that intranasal immunization with CPAF combined with cyclic-di-AMP (CDA) was well tolerated in female mice, induced CD4 T cells that produced IL-17A or IFN-gamma, reduced bacterial shedding, and shortened the duration of infection in mice challenged with Chlamydia muridarum. The study suggests that CDA has potential as a mucosal adjuvant for vaccines against Chlamydia genital tract infection. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]
- Published
- 2024
30. New Influenza A Virus Study Findings Recently Were Reported by Researchers at Georgia State University (Double-layered Protein Nanoparticles Conjugated With Truncated Flagellin Induce Improved Mucosal and Systemic Immune Responses In Mice).
- Abstract
Researchers at Georgia State University have developed a new vaccine formulation to combat respiratory infections caused by influenza A viruses. The vaccine consists of double-layered protein nanoparticles that are administered intranasally and are self-adjuvanted, meaning they enhance the immune response. In experiments with mice, the vaccine significantly increased both mucosal and systemic immune responses, including elevated levels of antigen-specific antibodies and increased populations of lung-resident memory B cells. The researchers also found that a slow-delivery strategy for the vaccine enhanced protective efficacy against different strains of influenza viruses. This study highlights the potential of intranasal immunization with protein nanoparticles to enhance immune responses and protect against influenza epidemics. [Extracted from the article]
- Published
- 2024
31. Research Reports from CECOS University Provide New Insights into Mucosal Vaccines (Intranasal Immunization of Pneumococcal pep27 Mutant Attenuates Allergic and Inflammatory Diseases by Upregulating Skin and Mucosal Tregs).
- Abstract
A research report from CECOS University in Peshawar, Pakistan discusses the potential benefits of mucosal vaccines in preventing pathogenic diseases. The report highlights the limitations of conventional immunization methods and the need for alternative options. The researchers propose intranasal immunization as a method to induce regulatory T (Treg) cells, which have shown promise in suppressing mucosal diseases. The study suggests that intranasal immunization with the pep27 mutant could attenuate allergic and inflammatory diseases by upregulating skin and mucosal Tregs. Further research is needed to explore the efficacy of this approach in clinical settings. [Extracted from the article]
- Published
- 2024
32. Intranasal delivery of a cDC1 targeted influenza vaccine with poly(I:C) enhances T cell responses and protects against influenza infection.
- Author
-
Lysén, Anna, Gudjonsson, Arnar, Tesfaye, Demo Yemane, Bobic, Sonja, Bern, Malin, Bogen, Bjarne, and Fossum, Even
- Subjects
- *
INTRANASAL administration , *T cells , *INFLUENZA vaccines , *FLU vaccine efficacy , *INFLUENZA - Abstract
Targeting antigens to dendritic cells represent a promising method for enhancing immune responses against specific antigens. However, many studies have focused on systemic delivery (intravenous or intraperitoneally) of targeted antigen, approaches that are not easily transferable to humans. Here we evaluate the efficacy of an influenza vaccine targeting Xcr1+ cDC1 administered by intranasal immunization. Intranasal delivery of antigen fused to the chemokine Xcl1, the ligand of Xcr1, resulted in specific uptake by lung CD103+ cDC1. Interestingly, intranasal immunization with influenza A/PR/8/34 haemagglutinin (HA) fused to Xcl1, formulated with poly(I:C), resulted in enhanced induction of antigen‐specific IFNγ+CD4+ and IFNγ+CD8+ T cell responses in lung compared non‐targeted anti‐NIP‐HA (αNIP‐HA). Induction of antibody responses was, however, similar in Xcl1‐HA and αNIP‐HA immunized mice, but significantly higher than in mice immunized with monomeric HA. Both Xcl1‐HA and αNIP‐HA vaccines induced full protection when mice were challenged with a lethal dose of influenza PR8 virus, reflecting the strong induction of HA‐specific antibodies. Our results demonstrate that i.n. delivery of Xcl1‐HA is a promising vaccine strategy for enhancing T cell responses in addition to inducing strong antibody responses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Mucosal Vaccination With Recombinant Tm- WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice.
- Author
-
Wei, Junfei, Hegde, Venkatesh L., Yanamandra, Ananta V., O'Hara, Madison P., Keegan, Brian, Jones, Kathryn M., Strych, Ulrich, Bottazzi, Maria Elena, Zhan, Bin, Sastry, K. Jagannadha, and Hotez, Peter J.
- Subjects
KILLER cells ,CELLULAR immunity ,CYTOTOXIC T cells ,IMMUNOGLOBULIN producing cells ,T cells - Abstract
Trichuriasis is one of the most common neglected tropical diseases of the world's poorest people. A recombinant vaccine composed of Tm- WAP49, an immunodominant antigen secreted by adult Trichuris stichocytes into the mucosa of the cecum to which the parasite attaches, is under development. The prototype is being evaluated in a mouse model of Trichuris muris infection, with the ultimate goal of producing a mucosal vaccine through intranasal delivery. Intranasal immunization of mice with Tm- WAP49 formulated with the adjuvant OCH, a truncated analog of alpha-GalCer with adjuvanticity to stimulate natural killer T cells (NKT) and mucosal immunity, induced significantly high levels of IgG and its subclasses (IgG1 and IgG2a) in immunized mice. This also resulted in a significant reduction of worm burden after challenge with T. muris -infective eggs. The addition of QS-21 adjuvant to this vaccine formulation further reduced worm counts. The improved protection from the dual-adjuvanted vaccine correlated with higher serum antibody responses (IgG, IgG1, IgG2a, IgA) as well as with the induction of antigen-specific IgA in the nasal mucosa. It was also associated with the robust cellular responses including functional subsets of CD4 T cells producing IL-4, and cytotoxic CD8 T cells expressing granzyme B. The worm reduction achieved by mucosal immunization was higher than that induced by subcutaneous immunization. Intranasal immunization also induced a significantly higher nasal mucosa-secreted antigen-specific IgA response, as well as higher functional cellular responses including CD4
+ IL4+ (Th1) and CD8+ GnzB+ (Th2) T cells, and antigen-specific INFγ-producing T cells in both spleen and MLNs and antibody-producing B cells (CD19+ B220+ /B220+ GL7+ ). Mucosal immunization further induced long-term T lymphocyte memory with increased central (CD62L+ CD44+ ) and effector (CD62L- CD44+ ) memory subsets of both CD4 and CD8 T cells at 60 days after the last immunization. In summary, intranasal immunization with recombinant Tm- WAP49 protein induced strong protection versus murine trichuriasis. It represents a promising vaccination approach against intestinal nematodes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Interleukin-22-induced β‑defensin-2 expression by intranasal immunization with Streptococcus pneumoniae RrgB epitopes
- Author
-
Diana Chusna Mufida, Antonius Dwi Saputra, Bagus Hermansyah, Dini Agustina, Muhammad Ali Shodikin, and Yunita Armiyanti
- Subjects
Intranasal Immunization ,Epitopes-based vaccine ,Protein RrgB Streptococcus pneumoniae ,β‑defensin-2 ,Medicine - Abstract
Background Streptococcus pneumoniae causes pneumococcal disease, which is responsible for millions of deaths worldwide. Various pneumococcal vaccine candidates have been developed to prevent S. pneumoniae infection, one of which is an epitope-based vaccine. This study aimed to prove that intranasal immunization with each of the five S. pneumoniae RrgB epitopes can induce a mucosal immune response by increasing the β-defensin-2 concentration through upregulation of interleukin (IL)-22 expression. Methods An experimental laboratory study was conducted using 28 male Wistar rats aged 3-4 months, that were randomly divided into 7 groups containing four rats each. Group 1 was given 40 mL of phosphate-buffered saline (PBS) only (control group). Group 2 was the adjuvant group that received 40 mL PBS containing 2 ìg cholera toxin B (CTB), and groups 3-7 were immunized with 40 mL PBS containing a combination of adjuvant and one of the five different S. pneumoniae RrgB epitopes. The concentrations of IL-22 and β-defensin-2 from nasal rinse examination were measured by means of ELISA. The Kruskal-Wallis test, followed by the Mann-Whitney post-hoc test were used for statistical analysis. Results Rats immunized with the adjuvant-epitope combination had significantly higher β-defensin-2 and IL-22 levels than the control group (p=0.030; p=0.018, respectively), according to the Kruskal-Wallis test. And the Mann-Whitney statistical test, showed there was a significant increase in β-defensin-2 and IL-22 levels. Conclusions Intranasal immunization with epitope 1 of the S. pneumoniae RrgB can increase β-defensin-2 expression significantly and has a greater potential to be developed into a pneumococcal vaccine.
- Published
- 2022
- Full Text
- View/download PDF
35. Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice
- Author
-
Junfei Wei, Venkatesh L. Hegde, Ananta V. Yanamandra, Madison P. O’Hara, Brian Keegan, Kathryn M. Jones, Ulrich Strych, Maria Elena Bottazzi, Bin Zhan, K. Jagannadha Sastry, and Peter J. Hotez
- Subjects
Trichuriasis ,vaccine ,Tm-WAP49 ,mucosal immunity ,intranasal immunization ,adjuvants ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Trichuriasis is one of the most common neglected tropical diseases of the world’s poorest people. A recombinant vaccine composed of Tm-WAP49, an immunodominant antigen secreted by adult Trichuris stichocytes into the mucosa of the cecum to which the parasite attaches, is under development. The prototype is being evaluated in a mouse model of Trichuris muris infection, with the ultimate goal of producing a mucosal vaccine through intranasal delivery. Intranasal immunization of mice with Tm-WAP49 formulated with the adjuvant OCH, a truncated analog of alpha-GalCer with adjuvanticity to stimulate natural killer T cells (NKT) and mucosal immunity, induced significantly high levels of IgG and its subclasses (IgG1 and IgG2a) in immunized mice. This also resulted in a significant reduction of worm burden after challenge with T. muris-infective eggs. The addition of QS-21 adjuvant to this vaccine formulation further reduced worm counts. The improved protection from the dual-adjuvanted vaccine correlated with higher serum antibody responses (IgG, IgG1, IgG2a, IgA) as well as with the induction of antigen-specific IgA in the nasal mucosa. It was also associated with the robust cellular responses including functional subsets of CD4 T cells producing IL-4, and cytotoxic CD8 T cells expressing granzyme B. The worm reduction achieved by mucosal immunization was higher than that induced by subcutaneous immunization. Intranasal immunization also induced a significantly higher nasal mucosa-secreted antigen-specific IgA response, as well as higher functional cellular responses including CD4+IL4+ (Th1) and CD8+GnzB+ (Th2) T cells, and antigen-specific INFγ-producing T cells in both spleen and MLNs and antibody-producing B cells (CD19+B220+/B220+GL7+). Mucosal immunization further induced long-term T lymphocyte memory with increased central (CD62L+CD44+) and effector (CD62L-CD44+) memory subsets of both CD4 and CD8 T cells at 60 days after the last immunization. In summary, intranasal immunization with recombinant Tm-WAP49 protein induced strong protection versus murine trichuriasis. It represents a promising vaccination approach against intestinal nematodes.
- Published
- 2022
- Full Text
- View/download PDF
36. Intranasal delivery of nanoparticles.
- Author
-
Friedrich, Ralf P, Cicha, Iwona, Tietze, Rainer, Unterweger, Harald, Lyer, Stefan, Janko, Christina, and Alexiou, Christoph
- Published
- 2022
- Full Text
- View/download PDF
37. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
- Author
-
Xueqiao Liu, Luongo, Cindy, Yumiko Matsuoka, Park, Hong-Su, Santos, Celia, Lijuan Yang, Moore, Ian N., Afroz, Sharmin, Johnson, Reed F., Lafont, Bernard A. P., Martens, Craig, Best, Sonja M., Munster, Vincent J., Hollý, Jaroslav, Yewdell, Jonathan W., Nouën, Cyril Le, Munir, Shirin, and Buchholz, Ursula J.
- Subjects
- *
COVID-19 vaccines , *HAMSTERS , *PARAINFLUENZA viruses , *SARS-CoV-2 , *VACCINATION of children , *COMMERCIAL products - Abstract
Single-dose vaccines with the ability to restrict SARS-CoV-2 replication in the respiratory tract are needed for all age groups, aiding efforts toward control of COVID-19. We developed a live intranasal vector vaccine for infants and children against COVID-19 based on replication-competent chimeric bovine/human parainfluenza virus type 3 (B/HPIV3) that express the native (S) or prefusionstabilized (S-2P) SARS-CoV-2 S spike protein, the major protective and neutralization antigen of SARS-CoV-2. B/HPIV3/S and B/HPIV3/S-2P replicated as efficiently as B/HPIV3 in vitro and stably expressed SARS-CoV-2 S. Prefusion stabilization increased S expression by B/HPIV3 in vitro. In hamsters, a single intranasal dose of B/HPIV3/S-2P induced significantly higher titers compared to B/HPIV3/S of serum SARS-CoV-2–neutralizing antibodies (12- fold higher), serum IgA and IgG to SARS-CoV-2 S protein (5-fold and 13-fold), and IgG to the receptor binding domain (10-fold). Antibodies exhibited broad neutralizing activity against SARSCoV-2 of lineages A, B.1.1.7, and B.1.351. Four weeks after immunization, hamsters were challenged intranasally with 104.5 50% tissue-culture infectious-dose (TCID50) of SARS-CoV-2. In B/HPIV3 empty vector-immunized hamsters, SARS-CoV-2 replicated to mean titers of 106.6 TCID50/g in lungs and 107 TCID50/g in nasal tissues and induced moderate weight loss. In B/HPIV3/S-immunized hamsters, SARS-CoV-2 challenge virus was reduced 20-fold in nasal tissues and undetectable in lungs. In B/HPIV3/S-2P–immunized hamsters, infectious challenge virus was undetectable in nasal tissues and lungs; B/HPIV3/S and B/HPIV3/S-2P completely protected against weight loss after SARS-CoV-2 challenge. B/HPIV3/S-2P is a promising vaccine candidate to protect infants and young children against HPIV3 and SARS-CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.
- Author
-
Li, Letian, Wang, Maopeng, Hao, Jiayi, Han, Jicheng, Fu, Tingting, Bai, Jieying, Tian, Mingyao, Jin, Ningyi, Zhu, Guangze, and Li, Chang
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *LACTOBACILLUS plantarum , *COVID-19 pandemic , *HUMORAL immunity , *IMMUNOGLOBULIN A , *INTESTINAL mucosa - Abstract
Coronavirus Disease 2019 (COVID-19) caused by a novel betacoronavirus SARS-CoV-2 has been an ongoing global pandemic. Several vaccines have been developed to control the COVID-19, but the potential effectiveness of the mucosal vaccine remains to be documented. In this study, we constructed a recombinant L. plantarum LP18:RBD expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein via the surface anchoring route. The amount of the RBD protein was maximally expressed under the culture condition with 200 ng/mL of inducer at 33 °C for 6 h. Further, we evaluated the immune response in mice via the intranasal administration of LP18:RBD. The results showed that the LP18:RBD significantly elicited RBD-specific mucosal IgA antibodies in respiratory tract and intestinal tract. The percentages of CD3 + CD4+ T cells in spleens of mice administrated with the LP18:RBD were also significantly increased. This indicated that LP18:RBD could induce a humoral immune response at the mucosa, and it could be used as a mucosal vaccine candidate against the SARS-CoV-2 infection. We provided the first experimental evidence that the recombinant L. plantarum LP18:RBD could initiate immune response in vivo, which implies that the mucosal immunization using recombinant LAB system could be a promising vaccination strategy to prevent the COVID-19 pandemic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Cross-Protection against Acute Staphylococcus aureus Lung Infection in Mice by a D-Glutamate Auxotrophic Vaccine Candidate
- Author
-
Patricia García, Maria P. Cabral, Alejandro Beceiro, Miriam Moscoso, and Germán Bou
- Subjects
live-attenuated vaccine ,Staphylococcus aureus ,auxotrophic ,intranasal immunization ,glutamate racemase gene ,D-amino acid transaminase gene ,Medicine - Abstract
Staphylococcus aureus is regarded as a threatening bacterial pathogen causing invasive pneumonia in healthcare settings and in the community. The continuous emergence of multidrug resistant strains is narrowing the treatment options for these infections. The development of an effective S. aureus vaccine is, therefore, a global priority. We have previously developed a vaccine candidate, 132 ΔmurI Δdat, which is auxotrophic for D-glutamate, and protects against sepsis caused by S. aureus. In the present study, we explored the potential of this vaccine candidate to prevent staphylococcal pneumonia, by using an acute lung infection model in BALB/c mice. Intranasal inoculation of the vaccine strain yielded transitory colonization of the lung tissue, stimulated production of relevant serum IgG and secretory IgA antibodies in the lung and distal vaginal mucosa and conferred cross-protection to acute pneumonia caused by clinically important S. aureus strains. Although these findings are promising, additional research is needed to minimize dose-dependent toxicity for safer intranasal immunization with this vaccine candidate.
- Published
- 2023
- Full Text
- View/download PDF
40. Bordetella pertussis antigens encapsulated into N-trimethyl chitosan nanoparticulate systems as a novel intranasal pertussis vaccine
- Author
-
Hamid Najminejad, Seyed Mehdi Kalantar, Ali Rezaei Mokarram, Mehran Dabaghian, Meghdad Abdollahpour-Alitappeh, Seyyed Mahmoud Ebrahimi, Majid Tebianian, Mahdi Fasihi Ramandi, and Mohammad Hasan Sheikhha
- Subjects
N-Trimethyl chitosan (TMC) ,Bordetella pertussis ,intranasal immunization ,nanoparticle vaccine ,Biotechnology ,TP248.13-248.65 ,Medical technology ,R855-855.5 - Abstract
The mucosal immune system serves as the first line of defense against Bordetella pertussis. Intranasal vaccination, due to its potential to induce systemic and mucosal immune responses, appears to prevent the initial adherence and colonization of the bacteria at the first point of contact. In the present study, two B. pertussis antigens, pertussis Toxoid (PTd) and Filamentous hemagglutinin (FHA), which play a very significant role in virulence and protection against pertussis, were encapsulate into N-trimethyl chitosan (TMC) nanoparticulate systems. After preparation of TMC nanoparticles (NPs), the NPs were characterized and their ability to induce efficient immune responses against B. pertussis was studied in a mouse model. Our findings showed that PTd + FHA-loaded TMC NPs have strong ability to induce IL-4, IL-17, IFN-γ, IgG, and IgA in the mouse model. Results from this study suggest that nasal administration of the PTd + FHA-loaded TMC NPs induced not only a systemic immune response but also a local mucosal response, which may improve the efficacy of pertussis prevention through respiratory tract transmission.
- Published
- 2019
- Full Text
- View/download PDF
41. Nano-Assembled Polyphosphazene Delivery System Enables Effective Intranasal Immunization with Nipah Virus Subunit Vaccine.
- Author
-
Leyva-Grado VH, Marin A, Hlushko R, Yunus AS, Promeneur D, Luckay A, Lazaro GG, Hamm S, Dimitrov AS, Broder CC, and Andrianov AK
- Subjects
- Animals, Particle Size, Materials Testing, Biocompatible Materials chemistry, Nanoparticles chemistry, Immunization, Organophosphorus Compounds chemistry, Organophosphorus Compounds administration & dosage, Administration, Intranasal, Polymers chemistry, Nipah Virus immunology, Viral Vaccines immunology, Viral Vaccines administration & dosage, Viral Vaccines chemistry, Vaccines, Subunit immunology, Vaccines, Subunit chemistry, Vaccines, Subunit administration & dosage
- Abstract
The ultimate vaccine against infections caused by Nipah virus should be capable of providing protection at the respiratory tract─the most probable port of entry for this pathogen. Intranasally delivered vaccines, which target nasal-associated lymphoid tissue and induce both systemic and mucosal immunity, are attractive candidates for enabling effective vaccination against this lethal disease. Herein, the water-soluble polyphosphazene delivery vehicle assembles into nanoscale supramolecular constructs with the soluble extracellular portion of the Hendra virus attachment glycoprotein─a promising subunit vaccine antigen against both Nipah and Hendra viruses. These supramolecular constructs signal through Toll-like receptor 7/8 and promote binding interactions with mucin─an important feature of effective mucosal adjuvants. High mass contrast of phosphorus-nitrogen backbone of the polymer enables a successful visualization of nanoconstructs in their vitrified state by cryogenic electron microscopy. Here, we characterize the self-assembly of polyphosphazene macromolecule with biologically relevant ligands by asymmetric flow field flow fractionation, dynamic light scattering, fluorescence spectrophotometry, and turbidimetric titration methods. Furthermore, a polyphosphazene-enabled intranasal Nipah vaccine candidate demonstrates the ability to induce immune responses in hamsters and shows superiority in inducing total IgG and neutralizing antibodies when benchmarked against the respective clinical stage alum adjuvanted vaccine. The results highlight the potential of polyphosphazene-enabled nanoassemblies in the development of intranasal vaccines.
- Published
- 2024
- Full Text
- View/download PDF
42. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern
- Author
-
Yang, Jingyi, Liu, Mei-Qin, Liu, Lin, Li, Xian, Xu, Mengxin, Lin, Haofeng, Liu, Shuning, Hu, Yunqi, Li, Bei, Liu, Bowen, Li, Min, Sun, Ying, Chen, Yao-Qing, Shi, Zheng-Li, and Yan, Huimin
- Published
- 2022
- Full Text
- View/download PDF
43. Immunization with HMW1 and HMW2 adhesins protects against colonization by heterologous strains of nontypeable Haemophilus influenzae.
- Author
-
Kadry, Nadia A., Porsch, Eric A., Hao Shen, and St. Geme III, Joseph W.
- Subjects
- *
HAEMOPHILUS influenzae , *LABORATORY mice , *IMMUNIZATION , *RESPIRATORY diseases , *ANTIBODY formation - Abstract
Nontypeable Haemophilus influenzae (NTHi) is a common cause of localized respiratory tract disease and results in significant morbidity. The pathogenesis of NTHi disease begins with nasopharyngeal colonization, and therefore, the prevention of colonization represents a strategy to prevent disease. The NTHi HMW1 and HMW2 proteins are a family of conserved adhesins that are present in 75 to 80% of strains and have been demonstrated to play a critical role in colonization of the upper respiratory tract in rhesus macaques. In this study, we examined the vaccine potential of HMW1 and HMW2 using a mouse model of nasopharyngeal colonization. Immunization with HMW1 and HMW2 by either the subcutaneous or the intranasal route resulted in a strain-specific antibody response associated with agglutination of bacteria and restriction of bacterial adherence. Despite the specificity of the antibody response, immunization resulted in protection against colonization by both the parent NTHi strain and heterologous strains expressing distinct HMW1 and HMW2 proteins. Pretreatment with antibody against IL-17A eliminated protection against heterologous strains, indicating that heterologous protection is IL-17A dependent. This work demonstrates the vaccine potential of the HMW1 and HMW2 proteins and highlights the importance of IL-17A in protection against diverse NTHi strains. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. State University of New York (SUNY) Albany Researcher Reports on Findings in Mucosal Vaccines (Inflammatory Profiles Induced by Intranasal Immunization with Ricin Toxin-immune Complexes).
- Abstract
A recent report from researchers at the State University of New York (SUNY) Albany explores the inflammatory response induced by intranasal immunization with ricin toxin-immune complexes (RICs). The study found that RICs can elicit a proinflammatory response in both local and systemic tissues, with cytokines and chemokines playing a role in this process. The findings have implications for the development of mucosal vaccines for biothreats and emerging infectious diseases. Further research is needed to better understand the fate of immune complexes following intranasal delivery. [Extracted from the article]
- Published
- 2024
45. Mercer University Researcher Publishes New Study Findings on Zika Virus (Intranasal Immunization for Zika in a Pre-Clinical Model).
- Subjects
ZIKA virus ,ANIMAL models in research ,IMMUNIZATION ,RESEARCH personnel ,MEDICAL personnel - Abstract
A recent study conducted by researchers at Mercer University in Atlanta, Georgia, explores the development of a microparticulate Zika vaccine that can be administered painlessly through intranasal immunization. The researchers used an inactivated whole Zika virus as the antigen and tested different adjuvants to stimulate the immune response. The study found that the vaccine elicited a robust humoral, cellular, and memory response in mice. However, the researchers suggest that multiple doses may be necessary to achieve the desired immunological response. This pre-clinical study provides valuable insights into the development of a pain-free Zika vaccine. [Extracted from the article]
- Published
- 2024
46. Double Auxotrophy to Improve the Safety of a Live Anti-Pseudomonas aeruginosa Vaccine
- Author
-
Víctor Fuentes-Valverde, Patricia García, Miriam Moscoso, and Germán Bou
- Subjects
live-attenuated vaccine ,Pseudomonas aeruginosa ,auxotrophy ,intranasal immunization ,glutamate racemase gene ,alanine racemase gene ,Medicine - Abstract
Pseudomonas aeruginosa is an opportunistic nosocomial pathogen that causes serious infections in the respiratory tract of immunocompromised or critically ill patients, and it is also a significant source of bacteremia. Treatment of these infections can be complicated due to the emergence of multidrug-resistant P. aeruginosa strains worldwide. Hence, the development of prophylactic vaccines is a priority for at-risk patients. We have previously developed a vaccine candidate with a single auxotrophy for D-glutamate, PAO1 ΔmurI, which protects against sepsis and acute pneumonia caused by P. aeruginosa. Given the paramount importance of safety in the development of live attenuated vaccines, we have improved the safety of the vaccine candidate by reducing the probability of a reversion to virulence by the inclusion of an additional auxotrophy for D-alanine. Single and double auxotrophs behaved in a similar manner in relation to the attenuation level, immunogenicity and protective efficacy, but the double auxotroph has the advantage of being more stable and safer as a candidate vaccine against respiratory infections caused by P. aeruginosa.
- Published
- 2022
- Full Text
- View/download PDF
47. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection
- Author
-
Wenxu Jia, Rudragouda Channappanavar, Chao Zhang, Mingxi Li, Haixia Zhou, Shuyuan Zhang, Panpan Zhou, Jiuyang Xu, Sisi Shan, Xuanling Shi, Xinquan Wang, Jincun Zhao, Dongming Zhou, Stanley Perlman, and Linqi Zhang
- Subjects
MERS-CoV vaccine ,chimpanzee adenoviral vector ,receptor binding domain (RBD) ,intranasal immunization ,monoclonal antibody ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
ABSTRACTThe recently identified Middle East Respiratory Syndrome Coronavirus (MERS-CoV) causes severe and fatal acute respiratory illness in humans. However, no approved prophylactic and therapeutic interventions are currently available. The MERS-CoV envelope spike protein serves as a crucial target for neutralizing antibodies and vaccine development, as it plays a critical role in mediating viral entry through interactions with the cellular receptor, dipeptidyl peptidase 4 (DPP4). Here, we constructed a recombinant rare serotype of the chimpanzee adenovirus 68 (AdC68) that expresses full-length MERS-CoV S protein (AdC68-S). Single intranasal immunization with AdC68-S induced robust and sustained neutralizing antibody and T cell responses in BALB/c mice. In a human DPP4 knock-in (hDPP4-KI) mouse model, it completely protected against lethal challenge with a mouse-adapted MERS-CoV (MERS-CoV-MA). Passive transfer of immune sera to naïve hDPP4-KI mice also provided survival advantages from lethal MERS-CoV-MA challenge. Analysis of sera absorption and isolated monoclonal antibodies from immunized mice demonstrated that the potent and broad neutralizing activity was largely attributed to antibodies targeting the receptor binding domain (RBD) of the S protein. These results show that AdC68-S can induce protective immune responses in mice and represent a promising candidate for further development against MERS-CoV infection in both dromedaries and humans.
- Published
- 2019
- Full Text
- View/download PDF
48. Intranasal Immunization with Zika Virus Envelope Domain III-Flagellin Fusion Protein Elicits Systemic and Mucosal Immune Responses and Protection against Subcutaneous and Intravaginal Virus Challenges
- Author
-
Chi-Hsun Chen, Chung-Chu Chen, Wei-Bo Wang, Vania Lionel, Chia-Chyi Liu, Li-Min Huang, and Suh-Chin Wu
- Subjects
intranasal immunization ,Zika virus ,domain III ,mucosal vaccine ,Pharmacy and materia medica ,RS1-441 - Abstract
Zika virus (ZIKV) infections in humans are mainly transmitted by the mosquito vectors, but human-to-human sexual transmission is also another important route. Developing a ZIKV mucosal vaccine that can elicit both systemic and mucosal immune responses is of particular interest. In this study, we constructed a recombinant ZIKV envelope DIII (ZDIII) protein genetically fused with Salmonella typhimurium flagellin (FliC-ZDIII) as a novel mucosal antigen for intranasal immunization. The results indicated that the FliC-ZDIII fusion proteins formulated with E. coli heat-labile enterotoxin B subunit (LTIIb-B5) adjuvant greatly increased the ZDIII-specific IgG, IgA, and neutralizing titers in sera, and the ZDIII-specific IgA titers in bronchoalveolar lavage and vaginal fluids. Protective immunity was further assessed by subcutaneous and intravaginal ZIKV challenges. The second-generation FliCΔD3-2ZDIII was shown to result in a reduced titer of anti-FliC IgG antibodies in sera and still retained the same levels of serum IgG, IgA, and neutralizing antibodies and mucosal IgA antibodies without compromising the vaccine antigenicity. Therefore, intranasal immunization with FliCΔD3-2ZDIII fusion proteins formulated with LTIIb-B5 adjuvant elicited the greatest protective immunity against subcutaneous and intravaginal ZIKV challenges. Our findings indicated that the combination of FliCΔD3-2ZDIII fusion proteins and LTIIb-B5 adjuvant for intranasal immunization can be used for developing ZIKV mucosal vaccines.
- Published
- 2022
- Full Text
- View/download PDF
49. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2
- Author
-
Ranjan Ramasamy
- Subjects
adaptive immunity ,age and SARS-CoV-2 infectivity ,COVID-19 vaccines ,human genetics and SARS-CoV-2 infectivity ,innate immunity ,intranasal immunization ,Microbiology ,QR1-502 - Abstract
Increasing evidence shows the nasal epithelium to be the initial site of SARS-CoV-2 infection, and that early and effective immune responses in the upper respiratory tract (URT) limit and eliminate the infection in the URT, thereby preventing infection of the lower respiratory tract and the development of severe COVID-19. SARS-CoV-2 interferes with innate immunity signaling and evolves mutants that can reduce antibody-mediated immunity in the URT. Recent genetic and immunological advances in understanding innate immunity to SARS-CoV-2 in the URT, and the ability of prior infections as well as currently available injectable and potential intranasal COVID-19 vaccines to generate anamnestic adaptive immunity in the URT, are reviewed. It is suggested that the more detailed investigation of URT immune responses to all types of COVID-19 vaccines, and the development of safe and effective COVID-19 vaccines for intranasal administration, are important needs.
- Published
- 2022
- Full Text
- View/download PDF
50. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
- Author
-
Li H, Sun H, Tao M, Han Q, Yu H, Li J, Lu X, Tong Q, Pu J, Sun Y, Liu L, Liu J, and Sun H
- Subjects
- Animals, Humans, Mice, Ferrets immunology, Hemagglutinin Glycoproteins, Influenza Virus genetics, Hemagglutinin Glycoproteins, Influenza Virus immunology, Immunity, Cellular, Immunity, Humoral, Immunity, Mucosal, Influenza in Birds immunology, Influenza in Birds prevention & control, Influenza in Birds transmission, Influenza in Birds virology, Pandemic Preparedness methods, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic adverse effects, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Administration, Intranasal, Poultry virology, Immunoglobulin A immunology, T-Lymphocytes immunology, Influenza A Virus, H5N1 Subtype chemistry, Influenza A Virus, H5N1 Subtype classification, Influenza A Virus, H5N1 Subtype genetics, Influenza A Virus, H5N1 Subtype immunology, Influenza A Virus, H5N6 Subtype chemistry, Influenza A Virus, H5N6 Subtype classification, Influenza A Virus, H5N6 Subtype genetics, Influenza A Virus, H5N6 Subtype immunology, Influenza Vaccines administration & dosage, Influenza Vaccines adverse effects, Influenza Vaccines genetics, Influenza Vaccines immunology, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control, Orthomyxoviridae Infections transmission, Orthomyxoviridae Infections virology, Parainfluenza Virus 5 genetics, Parainfluenza Virus 5 immunology, Parainfluenza Virus 5 metabolism
- Abstract
The global circulation of clade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) in poultry and wild birds, increasing mammal infections, continues to pose a public health threat and may even form a pandemic. An efficacious vaccine against H5Ny HPAIVs is crucial for emergency use and pandemic preparedness. In this study, we developed a parainfluenza virus 5 (PIV5)-based vaccine candidate expressing hemagglutinin (HA) protein of clade 2.3.4.4b H5 HPAIV, termed rPIV5-H5, and evaluated its safety and efficacy in mice and ferrets. Our results demonstrated that intranasal immunization with a single dose of rPIV5-H5 could stimulate H5-specific antibody responses, moreover, a prime-boost regimen using rPIV5-H5 stimulated robust humoral, cellular, and mucosal immune responses in mice. Challenge study showed that rPIV5-H5 prime-boost regimen provided sterile immunity against lethal clade 2.3.4.4b H5N1 virus infection in mice and ferrets. Notably, rPIV5-H5 prime-boost regimen provided protection in mice against challenge with lethal doses of heterologous clades 2.2, 2.3.2, and 2.3.4 H5N1, and clade 2.3.4.4h H5N6 viruses. These results revealed that rPIV5-H5 can elicit protective immunity against a diverse clade of highly pathogenic H5Ny virus infection in mammals, highlighting the potential of rPIV5-H5 as a pan-H5 influenza vaccine candidate for emergency use.IMPORTANCEClade 2.3.4.4b H5Ny highly pathogenic avian influenza viruses (HPAIVs) have been widely circulating in wild birds and domestic poultry all over the world, leading to infections in mammals, including humans. Here, we developed a recombinant PIV5-vectored vaccine candidate expressing the HA protein of clade 2.3.4.4b H5 virus. Intranasal immunization with rPIV5-H5 in mice induced airway mucosal IgA responses, high levels of antibodies, and robust T-cell responses. Importantly, rPIV5-H5 conferred complete protection in mice and ferrets against clade 2.3.4.4b H5N1 virus challenge, the protective immunity was extended against heterologous H5Ny viruses. Taken together, our data demonstrate that rPIV5-H5 is a promising vaccine candidate against diverse H5Ny influenza viruses in mammals., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.